peginterferon alfa-2a 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
5158 198153-51-4

Description:

MoleculeDescription

Synonyms:

  • peginterferon alfa-2a
  • pegasys
interferon alfa‑2a attached to polyethylene glycol
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
26 mcg P

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Oct. 16, 2002 FDA HOFFMAN-LA ROCHE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaemia 1846.58 16.58 1328 28394 292102 63167198
White blood cell count decreased 802.39 16.58 600 29122 138504 63320796
Platelet count decreased 583.81 16.58 462 29260 115660 63343640
Haemoglobin decreased 406.95 16.58 416 29306 145069 63314231
Anal pruritus 287.72 16.58 66 29656 601 63458699
Leukopenia 279.92 16.58 255 29467 77035 63382265
Dysgeusia 278.48 16.58 206 29516 46504 63412796
Exposure via direct contact 278.21 16.58 49 29673 83 63459217
Pancytopenia 252.39 16.58 267 29455 96666 63362634
Rash 238.44 16.58 686 29036 560185 62899115
Thrombocytopenia 236.21 16.58 321 29401 150836 63308464
Anorectal discomfort 222.02 16.58 72 29650 2567 63456733
Haemolytic anaemia 200.70 16.58 97 29625 10028 63449272
Red blood cell count decreased 187.36 16.58 154 29568 40491 63418809
Neutropenia 182.67 16.58 308 29414 174697 63284603
Viral load increased 181.50 16.58 53 29669 1321 63457979
Neutrophil count decreased 171.46 16.58 169 29553 56237 63403063
Influenza like illness 168.39 16.58 181 29541 66643 63392657
Depression 161.87 16.58 312 29410 196180 63263120
No adverse event 150.53 16.58 137 29585 41268 63418032
Pruritus 142.34 16.58 431 29291 361022 63098278
Fatigue 135.97 16.58 791 28931 887237 62572063
Asthenia 128.76 16.58 433 29289 383171 63076129
Nausea 115.95 16.58 738 28984 853733 62605567
Decreased appetite 104.94 16.58 306 29416 250746 63208554
Drug ineffective 93.76 16.58 221 29501 1044544 62414756
Hepatic cirrhosis 92.15 16.58 83 29639 24651 63434649
Ascites 88.24 16.58 102 29620 40626 63418674
Pyrexia 87.66 16.58 443 29279 470035 62989265
Hepatitis C 85.24 16.58 44 29678 5230 63454070
Condition aggravated 83.64 16.58 42 29680 402175 63057125
Arthropathy 81.13 16.58 8 29714 234784 63224516
Drug hypersensitivity 80.28 16.58 23 29699 310664 63148636
Joint swelling 78.04 16.58 28 29694 327638 63131662
Drug reaction with eosinophilia and systemic symptoms 77.12 16.58 87 29635 33749 63425551
Haemorrhoids 70.31 16.58 68 29654 22082 63437218
Toxicity to various agents 70.27 16.58 15 29707 247235 63212065
Drug intolerance 69.15 16.58 29 29693 308632 63150668
Rash pruritic 68.64 16.58 110 29612 59689 63399611
Dry skin 68.55 16.58 107 29615 56780 63402520
Blood bilirubin increased 67.35 16.58 85 29637 37055 63422245
Peripheral swelling 66.31 16.58 21 29701 265921 63193379
Chills 65.44 16.58 156 29566 113222 63346078
Rheumatoid arthritis 65.16 16.58 19 29703 253800 63205500
Insomnia 64.21 16.58 234 29488 215018 63244282
Irritability 63.05 16.58 76 29646 31618 63427682
Systemic lupus erythematosus 62.90 16.58 11 29711 208907 63250393
Weight decreased 62.63 16.58 276 29446 276522 63182778
Retinopathy 59.15 16.58 29 29693 3090 63456210
Retinal exudates 54.04 16.58 18 29704 698 63458602
Completed suicide 52.92 16.58 4 29718 145669 63313631
Product use in unapproved indication 52.66 16.58 10 29712 179070 63280230
Discomfort 52.18 16.58 8 29714 167366 63291934
Hyperthyroidism 48.37 16.58 46 29676 14627 63444673
Vomiting 46.03 16.58 431 29291 559186 62900114
Hypothyroidism 45.63 16.58 76 29646 42556 63416744
Hepatitis C RNA increased 45.19 16.58 11 29711 132 63459168
Myalgia 44.25 16.58 160 29562 146369 63312931
Therapeutic product effect incomplete 43.86 16.58 4 29718 125052 63334248
Musculoskeletal stiffness 43.52 16.58 16 29706 184602 63274698
Fall 42.60 16.58 74 29648 392260 63067040
Abdominal discomfort 42.16 16.58 53 29669 320832 63138468
Autoimmune thyroiditis 41.75 16.58 25 29697 3961 63455339
Hepatic failure 41.46 16.58 66 29656 35590 63423710
Proctalgia 41.05 16.58 29 29693 6081 63453219
Hypersensitivity 40.95 16.58 46 29676 292639 63166661
Hepatic enzyme increased 40.69 16.58 22 29700 202306 63256994
Hepatocellular carcinoma 40.41 16.58 20 29702 2174 63457126
Nasopharyngitis 40.10 16.58 36 29686 254221 63205079
Lower respiratory tract infection 39.73 16.58 7 29715 132300 63327000
Mobility decreased 39.62 16.58 5 29717 121154 63338146
Face oedema 39.44 16.58 48 29674 20164 63439136
Infection 39.16 16.58 30 29692 229143 63230157
Sarcoidosis 37.08 16.58 29 29693 7093 63452207
Jaundice 36.60 16.58 56 29666 29195 63430105
Poor quality product administered 36.22 16.58 21 29701 3135 63456165
COVID-19 36.19 16.58 5 29717 113098 63346202
Pain 34.87 16.58 204 29518 740424 62718876
Osteoarthritis 33.56 16.58 3 29719 95340 63363960
Hyperuricaemia 32.67 16.58 24 29698 5346 63453954
Extradural abscess 31.50 16.58 13 29709 924 63458376
Urate nephropathy 31.28 16.58 8 29714 119 63459181
Alopecia 31.27 16.58 267 29455 337269 63122031
Rash papular 30.16 16.58 37 29685 15665 63443635
Pericarditis 30.01 16.58 12 29710 131567 63327733
Helicobacter infection 29.92 16.58 4 29718 92781 63366519
Impaired healing 29.56 16.58 6 29716 102536 63356764
Vogt-Koyanagi-Harada disease 29.54 16.58 8 29714 150 63459150
Aquagenic pruritus 28.79 16.58 6 29716 33 63459267
Glossodynia 28.58 16.58 25 29697 178851 63280449
Basedow's disease 28.24 16.58 9 29713 303 63458997
Transfusion 27.85 16.58 35 29687 15182 63444118
Hepatic encephalopathy 27.40 16.58 30 29692 11252 63448048
Haematocrit decreased 26.98 16.58 58 29664 39282 63420018
Product administration error 26.79 16.58 42 29680 22355 63436945
Death 26.77 16.58 88 29634 374293 63085007
C-reactive protein increased 26.36 16.58 6 29716 94701 63364599
Epistaxis 25.95 16.58 84 29638 72641 63386659
Oxygen saturation decreased 25.92 16.58 5 29717 88580 63370720
Toxic skin eruption 25.79 16.58 31 29691 12854 63446446
Tongue pigmentation 25.50 16.58 5 29717 19 63459281
Retinal haemorrhage 25.36 16.58 20 29702 4949 63454351
Disease progression 25.18 16.58 13 29709 122745 63336555
Psoriatic arthropathy 25.07 16.58 6 29716 91514 63367786
Autoimmune hepatitis 24.91 16.58 25 29697 8485 63450815
Cryoglobulinaemia 24.57 16.58 9 29713 464 63458836
Porphyria non-acute 24.56 16.58 8 29714 289 63459011
Atrial fibrillation 24.45 16.58 12 29710 116624 63342676
Lymphadenopathy 24.45 16.58 55 29667 38403 63420897
Arthralgia 24.13 16.58 162 29560 569548 62889752
Injury 24.00 16.58 3 29719 73244 63386056
Swelling 23.88 16.58 59 29663 275319 63183981
Thyroid function test abnormal 23.78 16.58 17 29705 3630 63455670
Drug abuse 23.69 16.58 3 29719 72515 63386785
Erythema nodosum 23.55 16.58 19 29703 4856 63454444
Virologic failure 23.00 16.58 13 29709 1849 63457451
Cutaneous sarcoidosis 22.90 16.58 8 29714 359 63458941
Blood thyroid stimulating hormone increased 22.66 16.58 22 29700 7172 63452128
Product quality issue 22.47 16.58 51 29671 35814 63423486
Mental disorder 22.30 16.58 42 29680 25877 63433423
Febrile neutropenia 22.21 16.58 14 29708 118435 63340865
Hypotension 21.67 16.58 61 29661 272543 63186757
Crying 21.56 16.58 39 29683 23304 63435996
Gingival bleeding 21.54 16.58 28 29694 12559 63446741
Irritable bowel syndrome 21.43 16.58 6 29716 82406 63376894
Inflammation 21.38 16.58 6 29716 82267 63377033
Wheezing 21.34 16.58 9 29713 95586 63363714
Hypertension 21.11 16.58 64 29658 279239 63180061
Blood pressure increased 21.01 16.58 27 29695 162035 63297265
Vision blurred 20.98 16.58 92 29630 91832 63367468
Facial paralysis 20.63 16.58 29 29693 14012 63445288
Pregnancy 20.49 16.58 50 29672 36786 63422514
Anger 20.22 16.58 27 29695 12429 63446871
Intentional overdose 20.04 16.58 5 29717 74147 63385153
Maternal exposure during pregnancy 19.99 16.58 46 29676 220016 63239284
Off label use 19.88 16.58 211 29511 674251 62785049
VIIIth nerve lesion 19.51 16.58 4 29718 20 63459280
Loss of personal independence in daily activities 18.94 16.58 11 29711 97279 63362021
Cardiac arrest 18.68 16.58 10 29712 92535 63366765
Hepatic cancer 18.59 16.58 16 29706 4471 63454829
Full blood count decreased 18.57 16.58 39 29683 25985 63433315
Sinusitis 18.54 16.58 50 29672 226603 63232697
Viral load decreased 18.49 16.58 4 29718 27 63459273
Angular cheilitis 18.45 16.58 8 29714 643 63458657
Guillain-Barre syndrome 18.44 16.58 15 29707 3878 63455422
Alanine aminotransferase increased 18.01 16.58 96 29626 103674 63355626
Erythema annulare 17.98 16.58 5 29717 104 63459196
Dry mouth 17.82 16.58 78 29644 77785 63381515
Hyperbilirubinaemia 17.57 16.58 24 29698 11290 63448010
Aplastic anaemia 17.50 16.58 22 29700 9547 63449753
Injection site pain 17.48 16.58 21 29701 129779 63329521
Bulimia nervosa 17.38 16.58 7 29715 467 63458833
Exposure via father 17.24 16.58 6 29716 266 63459034
Demyelinating polyneuropathy 17.04 16.58 8 29714 774 63458526
Adverse drug reaction 17.01 16.58 8 29714 79706 63379594
Dehydration 17.01 16.58 139 29583 173215 63286085
Rash erythematous 16.91 16.58 51 29671 42459 63416841
Gastrointestinal disorder 16.87 16.58 22 29700 131217 63328083
Nasal congestion 16.67 16.58 5 29717 65655 63393645

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaemia 1212.13 14.56 1299 32679 232036 34690917
White blood cell count decreased 778.45 14.56 683 33295 94762 34828191
Rash 699.01 14.56 963 33015 221789 34701164
Platelet count decreased 440.75 14.56 561 33417 119156 34803797
Pruritus 372.10 14.56 565 33413 141416 34781537
Influenza like illness 367.01 14.56 264 33714 27370 34895583
Fatigue 360.60 14.56 974 33004 369679 34553274
Anorectal discomfort 338.01 14.56 110 33868 1854 34921099
Depression 274.88 14.56 401 33577 96697 34826256
Dysgeusia 273.92 14.56 218 33760 26279 34896674
Haemoglobin decreased 240.59 14.56 425 33553 120347 34802606
Anal pruritus 231.24 14.56 57 33921 319 34922634
Thrombocytopenia 214.33 14.56 470 33508 155777 34767176
Leukopenia 206.53 14.56 279 33699 62577 34860376
Insomnia 200.83 14.56 361 33617 103546 34819407
Irritability 171.64 14.56 162 33816 24528 34898425
Viral load increased 157.02 14.56 67 33911 2460 34920493
Hepatic cirrhosis 152.79 14.56 130 33848 17184 34905769
Red blood cell count decreased 140.66 14.56 157 33821 28933 34894020
Hepatitis C 137.48 14.56 97 33881 9733 34913220
Neutropenia 137.37 14.56 398 33580 156380 34766573
Neutrophil count decreased 128.58 14.56 200 33778 50904 34872049
Exposure via direct contact 128.52 14.56 24 33954 19 34922934
Nausea 120.40 14.56 648 33330 339260 34583693
Haemorrhoids 119.61 14.56 105 33873 14470 34908483
Pancytopenia 114.37 14.56 272 33706 94885 34828068
Toxicity to various agents 112.86 14.56 28 33950 200334 34722619
Retinal exudates 108.76 14.56 37 33941 719 34922234
Dry skin 99.79 14.56 137 33841 31150 34891803
Headache 92.62 14.56 413 33565 200222 34722731
Rash pruritic 92.05 14.56 122 33856 26819 34896134
No adverse event 86.43 14.56 109 33869 22818 34900135
Product use in unapproved indication 85.11 14.56 8 33970 117491 34805462
Febrile neutropenia 77.23 14.56 19 33959 136830 34786123
Retinopathy 75.80 14.56 38 33940 2026 34920927
Malignant neoplasm progression 72.63 14.56 3 33975 88043 34834910
Hypotension 70.51 14.56 67 33911 221582 34701371
Drug abuse 68.53 14.56 8 33970 99088 34823865
Decreased appetite 67.49 14.56 330 33648 166062 34756891
Hepatocellular carcinoma 67.49 14.56 57 33921 7452 34915501
Abortion spontaneous 67.18 14.56 22 33956 378 34922575
Ascites 64.60 14.56 141 33837 46430 34876523
Proctalgia 63.20 14.56 49 33929 5674 34917279
Acute kidney injury 59.69 14.56 130 33848 304858 34618095
Depressed mood 59.20 14.56 83 33895 19234 34903719
Death 58.15 14.56 196 33782 397853 34525100
Fall 57.05 14.56 68 33910 202817 34720136
Bradycardia 54.95 14.56 5 33973 75413 34847540
Blood bilirubin increased 53.17 14.56 116 33862 38180 34884773
Completed suicide 52.76 14.56 15 33963 98153 34824800
Weight decreased 52.17 14.56 321 33657 175980 34746973
Condition aggravated 51.32 14.56 67 33911 192129 34730824
Off label use 51.30 14.56 222 33756 419302 34503651
Product use issue 49.44 14.56 3 33975 63213 34859740
Therapy non-responder 45.97 14.56 111 33867 39035 34883918
Hepatic cancer 45.81 14.56 48 33930 8227 34914726
Pyrexia 45.61 14.56 509 33469 332504 34590449
Disease progression 44.26 14.56 25 33953 108052 34814901
Facial paralysis 43.60 14.56 53 33925 10681 34912272
Cardiac failure congestive 42.44 14.56 14 33964 83256 34839697
Pregnancy of partner 42.31 14.56 15 33963 331 34922622
Sarcoidosis 41.54 14.56 29 33949 2859 34920094
Alopecia 41.14 14.56 80 33898 24275 34898678
Mood swings 40.51 14.56 44 33934 7857 34915096
Infusion related reaction 40.07 14.56 3 33975 53054 34869899
Hepatic encephalopathy 39.03 14.56 59 33919 14626 34908327
Hyponatraemia 38.61 14.56 16 33962 82675 34840278
Retinal haemorrhage 38.44 14.56 35 33943 5054 34917899
C-reactive protein increased 38.31 14.56 4 33974 54094 34868859
Myalgia 37.06 14.56 171 33807 83939 34839014
Varices oesophageal 36.86 14.56 30 33948 3725 34919228
Respiratory failure 36.64 14.56 31 33947 108541 34814412
Chills 36.62 14.56 166 33812 80877 34842076
Haemolytic anaemia 36.62 14.56 48 33930 10431 34912522
Atrial fibrillation 36.56 14.56 39 33939 122354 34800599
Hyperkalaemia 36.55 14.56 11 33967 69378 34853575
Injection site rash 36.24 14.56 31 33947 4122 34918831
Tachycardia 35.58 14.56 19 33959 84753 34838200
Peripheral swelling 35.43 14.56 15 33963 76526 34846427
Hepatic failure 35.40 14.56 93 33885 34438 34888515
Blood pressure increased 35.18 14.56 21 33957 88081 34834872
Acute stress disorder 34.91 14.56 11 33967 166 34922787
Dry mouth 34.84 14.56 85 33893 30080 34892873
Asthenia 34.01 14.56 376 33602 244875 34678078
Pregnancy 33.46 14.56 12 33966 274 34922679
Therapeutic product effect incomplete 32.73 14.56 5 33973 50536 34872417
Drug hypersensitivity 32.43 14.56 19 33959 80510 34842443
Cryoglobulinaemia 31.40 14.56 13 33965 442 34922511
Intentional product misuse 30.74 14.56 4 33974 45607 34877346
Normal newborn 30.69 14.56 10 33968 169 34922784
Treatment failure 30.20 14.56 107 33871 46590 34876363
Hepatitis C RNA increased 29.41 14.56 11 33967 284 34922669
Autoimmune hepatitis 29.11 14.56 28 33950 4332 34918621
Drug reaction with eosinophilia and systemic symptoms 28.97 14.56 84 33894 32928 34890025
Vision blurred 28.60 14.56 104 33874 45859 34877094
Wrong dose 27.96 14.56 13 33965 586 34922367
Porphyria non-acute 27.22 14.56 12 33966 477 34922476
Facial paresis 27.10 14.56 23 33955 3026 34919927
Mucosal inflammation 26.98 14.56 3 33975 38619 34884334
Gastrointestinal haemorrhage 26.63 14.56 28 33950 88449 34834504
Therapy responder 26.49 14.56 9 33969 174 34922779
Oesophageal varices haemorrhage 26.47 14.56 23 33955 3123 34919830
Toxic skin eruption 26.45 14.56 43 33935 11342 34911611
Hypoglycaemia 26.44 14.56 10 33968 54630 34868323
General physical health deterioration 26.42 14.56 53 33925 128216 34794737
Product administration error 25.57 14.56 52 33926 16292 34906661
Hypoxia 25.17 14.56 11 33967 55084 34867869
Virologic failure 24.48 14.56 23 33955 3457 34919496
Injection site erythema 24.18 14.56 50 33928 15849 34907104
Therapeutic product effect decreased 23.52 14.56 3 33975 34740 34888213
Suicidal ideation 23.14 14.56 89 33889 40299 34882654
Tinnitus 22.49 14.56 56 33922 20062 34902891
Hospitalisation 22.10 14.56 14 33964 56888 34866065
Oral herpes 21.90 14.56 27 33951 5520 34917433
Portal hypertension 21.49 14.56 23 33955 4039 34918914
Prostate cancer 21.40 14.56 6 33972 39643 34883310
Cardiac arrest 21.31 14.56 38 33940 96121 34826832
Viral load 21.29 14.56 6 33972 60 34922893
Pulmonary oedema 20.91 14.56 10 33968 47519 34875434
Hypertension 20.63 14.56 66 33912 136377 34786576
Chronic obstructive pulmonary disease 20.47 14.56 11 33967 48907 34874046
Borderline personality disorder 19.89 14.56 9 33969 381 34922572
Pneumonia aspiration 19.73 14.56 8 33970 41895 34881058
Serum ferritin increased 19.71 14.56 27 33951 6119 34916834
Mood altered 19.70 14.56 33 33945 8919 34914034
Product quality issue 19.66 14.56 48 33930 16987 34905966
Myocardial infarction 19.42 14.56 57 33921 121028 34801925
Disturbance in attention 19.01 14.56 62 33916 25883 34897070
Ear injury 18.85 14.56 5 33973 39 34922914
Somnolence 18.79 14.56 51 33927 111065 34811888
Granulocyte count decreased 18.73 14.56 11 33967 804 34922149
Skin disorder 18.73 14.56 41 33937 13514 34909439
Coronary artery disease 18.60 14.56 12 33966 48293 34874660
Acute myocardial infarction 18.53 14.56 15 33963 53704 34869249
Oral lichen planus 18.52 14.56 7 33971 186 34922767
Haematuria 18.52 14.56 13 33965 50053 34872900
Smooth muscle antibody positive 18.47 14.56 4 33974 11 34922942
Cerebrovascular accident 18.36 14.56 34 33944 84777 34838176
Peritonitis bacterial 18.34 14.56 26 33952 6084 34916869
Premature rupture of membranes 18.22 14.56 4 33974 12 34922941
Photosensitivity reaction 18.13 14.56 35 33943 10559 34912394
Metabolic acidosis 18.01 14.56 10 33968 43670 34879283
International normalised ratio increased 17.89 14.56 12 33966 47315 34875638
Blood iron increased 17.88 14.56 11 33967 875 34922078
Wheezing 17.78 14.56 9 33969 41393 34881560
Deafness unilateral 17.68 14.56 15 33963 1972 34920981
Anger 17.63 14.56 37 33941 11847 34911106
Cardiac disorder 17.60 14.56 10 33968 43116 34879837
Skin burning sensation 17.37 14.56 22 33956 4621 34918332
Flushing 17.32 14.56 5 33973 32415 34890538
Abortion induced 17.29 14.56 6 33972 124 34922829
Anaphylactic reaction 17.22 14.56 5 33973 32296 34890657
Skin irritation 17.13 14.56 24 33954 5553 34917400
Memory impairment 16.84 14.56 85 33893 43233 34879720
Basedow's disease 16.77 14.56 5 33973 62 34922891
Psychotic disorder 16.64 14.56 57 33921 24395 34898558
Intentional overdose 16.61 14.56 11 33967 43663 34879290
Pain in extremity 16.58 14.56 65 33913 126448 34796505
Drug interaction 16.23 14.56 141 33837 225805 34697148
Musculoskeletal stiffness 16.14 14.56 13 33965 46667 34876286
Hypercatabolism 15.74 14.56 3 33975 3 34922950
Gingival bleeding 15.67 14.56 26 33952 6974 34915979
Homicidal ideation 15.64 14.56 16 33962 2666 34920287
Alanine aminotransferase increased 15.63 14.56 133 33845 80682 34842271
Mental disorder 15.62 14.56 41 33937 15168 34907785
Hepatitis C RNA positive 15.45 14.56 6 33972 172 34922781
Vogt-Koyanagi-Harada disease 15.26 14.56 5 33973 86 34922867
Rash papular 15.25 14.56 32 33946 10246 34912707
Rash erythematous 15.10 14.56 56 33922 24921 34898032
Lower respiratory tract infection 14.96 14.56 6 33972 31631 34891322
Jaundice 14.90 14.56 66 33912 31816 34891137
Nephrotic syndrome 14.86 14.56 26 33952 7277 34915676
Product dose omission issue 14.75 14.56 63 33915 119648 34803305
Depressed level of consciousness 14.72 14.56 12 33966 42829 34880124
Injection site dryness 14.67 14.56 4 33974 35 34922918
Sudden hearing loss 14.67 14.56 10 33968 948 34922005
Affect lability 14.65 14.56 18 33960 3665 34919288
Haemorrhoids thrombosed 14.60 14.56 6 33972 200 34922753
Cardiac failure 14.59 14.56 43 33935 91205 34831748
Liver transplant 14.57 14.56 15 33963 2519 34920434

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaemia 2144.21 14.27 1836 41852 443179 79257521
White blood cell count decreased 1288.62 14.27 958 42730 187330 79513370
Platelet count decreased 826.30 14.27 751 42937 193913 79506787
Rash 499.84 14.27 1024 42664 577334 79123366
Leukopenia 482.66 14.27 444 43244 116069 79584631
Haemoglobin decreased 473.59 14.27 595 43093 221524 79479176
Thrombocytopenia 433.25 14.27 624 43064 264635 79436065
Influenza like illness 351.99 14.27 301 43387 71406 79629294
Dysgeusia 328.54 14.27 263 43425 56914 79643786
Pancytopenia 323.03 14.27 425 43263 165320 79535380
Neutrophil count decreased 295.24 14.27 308 43380 93651 79607049
Pruritus 295.04 14.27 660 43028 393988 79306712
Neutropenia 290.47 14.27 545 43143 287165 79413535
Anal pruritus 285.54 14.27 70 43618 731 79699969
Depression 282.97 14.27 460 43228 216330 79484370
Fatigue 267.42 14.27 1109 42579 928618 78772082
Anorectal discomfort 259.47 14.27 91 43597 3520 79697180
Insomnia 190.65 14.27 417 43271 244753 79455947
Hepatitis C 190.46 14.27 104 43584 11821 79688879
Red blood cell count decreased 186.79 14.27 192 43496 57321 79643379
Viral load increased 184.26 14.27 67 43621 2881 79697819
Irritability 184.24 14.27 164 43524 40980 79659720
Haemolytic anaemia 168.72 14.27 111 43577 17709 79682991
Hepatic cirrhosis 156.00 14.27 139 43549 34767 79665933
Toxicity to various agents 148.64 14.27 26 43662 421514 79279186
Dry skin 131.67 14.27 174 43514 67821 79632879
Blood bilirubin increased 130.59 14.27 171 43517 66061 79634639
Decreased appetite 125.15 14.27 442 43246 341976 79358724
Retinal exudates 123.88 14.27 40 43648 1195 79699505
Hepatocellular carcinoma 117.89 14.27 69 43619 8952 79691748
Ascites 114.57 14.27 172 43516 75390 79625310
Retinopathy 113.08 14.27 51 43637 3840 79696860
Infusion related reaction 112.09 14.27 3 43685 230234 79470466
Haemorrhoids 106.99 14.27 104 43584 29024 79671676
Pyrexia 104.64 14.27 682 43006 678027 79022673
Nausea 103.00 14.27 883 42805 956313 78744387
Asthenia 99.14 14.27 546 43142 511143 79189557
Product use issue 94.41 14.27 5 43683 209817 79490883
Condition aggravated 93.88 14.27 82 43606 501042 79199658
Drug hypersensitivity 91.99 14.27 25 43663 298891 79401809
Product use in unapproved indication 89.13 14.27 15 43673 250344 79450356
Completed suicide 89.12 14.27 14 43674 245753 79454947
Peripheral swelling 82.11 14.27 23 43665 269594 79431106
Rash pruritic 81.28 14.27 143 43545 71486 79629214
Joint swelling 80.14 14.27 29 43659 288617 79412083
Fall 79.59 14.27 90 43598 487539 79213161
Weight decreased 78.28 14.27 393 43295 354805 79345895
Arthropathy 77.30 14.27 5 43683 177106 79523594
Hepatic failure 75.75 14.27 127 43561 61085 79639615
Drug reaction with eosinophilia and systemic symptoms 72.56 14.27 128 43560 64116 79636584
COVID-19 70.17 14.27 4 43684 157670 79543030
Therapeutic product effect decreased 67.62 14.27 6 43682 163857 79536843
Drug abuse 67.02 14.27 6 43682 162685 79538015
Hypotension 66.81 14.27 86 43602 440231 79260469
Febrile neutropenia 66.19 14.27 22 43666 230977 79469723
Myalgia 62.89 14.27 234 43454 185407 79515293
Drug intolerance 61.60 14.27 34 43654 264085 79436615
No adverse event 59.71 14.27 87 43601 37105 79663595
Oxygen saturation decreased 58.27 14.27 3 43685 129044 79571656
Drug ineffective 58.27 14.27 351 43337 1080562 78620138
Chills 57.66 14.27 206 43482 160028 79540672
Hepatic encephalopathy 56.54 14.27 68 43620 24098 79676602
Lower respiratory tract infection 55.35 14.27 4 43684 129216 79571484
Musculoskeletal stiffness 55.02 14.27 14 43674 174994 79525706
Death 53.82 14.27 147 43541 566367 79134333
Proctalgia 53.16 14.27 44 43644 9957 79690743
Virologic failure 51.99 14.27 31 43657 4160 79696540
Retinal haemorrhage 51.89 14.27 40 43648 8177 79692523
Therapeutic product effect incomplete 51.48 14.27 8 43680 141637 79559063
Rheumatoid arthritis 49.82 14.27 26 43662 208444 79492256
Off label use 49.66 14.27 293 43395 906922 78793778
Exposure via direct contact 49.55 14.27 11 43677 71 79700629
Sarcoidosis 49.23 14.27 39 43649 8296 79692404
Hypersensitivity 48.91 14.27 43 43645 262196 79438504
Hyperuricaemia 48.80 14.27 45 43643 11754 79688946
Wound 48.62 14.27 4 43684 116175 79584525
Mobility decreased 46.51 14.27 6 43682 122169 79578531
Hyperbilirubinaemia 46.29 14.27 62 43626 24456 79676244
Disease progression 45.54 14.27 22 43666 184340 79516360
C-reactive protein increased 45.30 14.27 8 43680 129019 79571681
Toxic skin eruption 44.60 14.27 58 43630 22235 79678465
Alanine aminotransferase increased 43.14 14.27 190 43498 162380 79538320
Autoimmune hepatitis 43.13 14.27 42 43646 11741 79688959
Depressed mood 42.83 14.27 87 43601 48393 79652307
Jaundice 42.77 14.27 92 43596 53257 79647443
Blood pressure increased 42.72 14.27 32 43656 211328 79489372
Varices oesophageal 41.90 14.27 31 43657 5960 79694740
Basedow's disease 41.44 14.27 12 43676 246 79700454
Mood swings 40.20 14.27 52 43636 19828 79680872
Hyperthyroidism 40.16 14.27 55 43633 22154 79678546
Facial paralysis 39.34 14.27 53 43635 21019 79679681
Autoimmune thyroiditis 39.17 14.27 26 43662 4207 79696493
Cutaneous sarcoidosis 38.16 14.27 13 43675 460 79700240
Headache 37.40 14.27 533 43155 653239 79047461
Intentional product misuse 35.44 14.27 5 43683 95160 79605540
Vision blurred 35.42 14.27 133 43555 105765 79594935
Atrial fibrillation 35.05 14.27 34 43654 197852 79502848
Nasopharyngitis 35.04 14.27 53 43635 253828 79446872
Hepatic cancer 33.88 14.27 35 43653 10494 79690206
Systemic lupus erythematosus 33.88 14.27 12 43676 121137 79579563
Bradycardia 33.74 14.27 16 43672 135541 79565159
Cardiac failure congestive 33.66 14.27 18 43670 142384 79558316
Wheezing 33.59 14.27 11 43677 116653 79584047
Hyponatraemia 33.34 14.27 29 43659 177819 79522881
Porphyria non-acute 32.34 14.27 13 43675 736 79699964
Gingival bleeding 32.02 14.27 42 43646 16234 79684466
Osteoarthritis 31.56 14.27 5 43683 87304 79613396
Injury 31.52 14.27 3 43685 77493 79623207
Acute stress disorder 31.17 14.27 11 43677 433 79700267
Cryoglobulinaemia 31.00 14.27 13 43675 820 79699880
Dry mouth 30.65 14.27 112 43576 87907 79612793
Tinnitus 30.56 14.27 72 43616 44261 79656439
Acute kidney injury 30.35 14.27 164 43524 519240 79181460
Injection site rash 30.28 14.27 43 43645 17911 79682789
Blood cholesterol increased 29.80 14.27 5 43683 83715 79616985
Face oedema 29.13 14.27 54 43634 28082 79672618
Vogt-Koyanagi-Harada disease 28.84 14.27 9 43679 240 79700460
Psychotic disorder 28.27 14.27 67 43621 41335 79659365
Hepatitis C RNA increased 28.04 14.27 10 43678 406 79700294
Hypothyroidism 27.71 14.27 77 43611 52315 79648385
Alopecia 27.61 14.27 219 43469 231136 79469564
Hypoxia 27.57 14.27 11 43677 103232 79597468
Erythema nodosum 27.44 14.27 23 43665 5294 79695406
Urate nephropathy 27.18 14.27 8 43680 174 79700526
Smooth muscle antibody positive 27.09 14.27 8 43680 176 79700524
Pain in extremity 26.67 14.27 106 43582 364432 79336268
Skin disorder 26.59 14.27 58 43630 33885 79666815
Suicidal ideation 26.46 14.27 97 43591 76243 79624457
Flushing 25.98 14.27 8 43680 88260 79612440
Anger 25.89 14.27 39 43649 17123 79683577
Deafness unilateral 25.82 14.27 20 43668 4118 79696582
Discomfort 25.39 14.27 19 43669 125598 79575102
Pain 25.34 14.27 255 43433 703547 78997153
Psoriatic arthropathy 24.97 14.27 6 43682 77993 79622707
Hyperkalaemia 24.85 14.27 16 43672 114382 79586318
Injection site dermatitis 24.72 14.27 5 43683 19 79700681
Eczema 24.63 14.27 63 43625 40755 79659945
Hepatitis C RNA positive 24.58 14.27 8 43680 245 79700455
Infection 24.20 14.27 61 43627 241651 79459049
Peritonitis bacterial 24.17 14.27 28 43660 9539 79691161
Intentional overdose 24.16 14.27 14 43674 105946 79594754
Type 1 diabetes mellitus 24.09 14.27 24 43664 6895 79693805
Erythema multiforme 23.68 14.27 38 43650 17613 79683087
Skin irritation 23.67 14.27 30 43658 11210 79689490
Extradural abscess 23.62 14.27 13 43675 1499 79699201
Aspartate aminotransferase increased 23.48 14.27 143 43545 138498 79562202
Hepatic enzyme increased 23.42 14.27 40 43648 182570 79518130
Disturbance in attention 23.35 14.27 71 43617 50730 79649970
Helicobacter infection 23.04 14.27 5 43683 69699 79631001
Cardiac arrest 22.71 14.27 37 43651 172059 79528641
Somnolence 22.64 14.27 62 43626 238919 79461781
Skin lesion 22.63 14.27 62 43626 41782 79658918
Rash papular 22.61 14.27 42 43646 21874 79678826
Wrong dose 22.25 14.27 13 43675 1681 79699019
Epistaxis 22.14 14.27 120 43568 111395 79589305
Hospitalisation 22.14 14.27 12 43676 94224 79606476
Inflammation 21.93 14.27 12 43676 93741 79606959
Tongue pigmentation 21.70 14.27 5 43683 39 79700661
Granulocyte count decreased 21.46 14.27 13 43675 1795 79698905
Oesophageal varices haemorrhage 21.20 14.27 18 43670 4218 79696482
Photosensitivity reaction 21.19 14.27 40 43648 21087 79679613
Respiratory failure 21.09 14.27 42 43646 180869 79519831
Dermatitis 20.93 14.27 40 43648 21281 79679419
Bilirubin conjugated increased 20.75 14.27 20 43668 5519 79695181
Product dose omission issue 20.73 14.27 68 43620 247469 79453231
Hypertension 20.72 14.27 102 43586 330890 79369810
Anaphylactic reaction 20.66 14.27 10 43678 83733 79616967
Aplastic anaemia 20.62 14.27 36 43652 17869 79682831
Liver transplant 20.52 14.27 18 43670 4405 79696295
Stress 20.43 14.27 9 43679 79603 79621097
Bulimia nervosa 20.35 14.27 7 43681 255 79700445
Therapy responder 20.03 14.27 8 43680 445 79700255
Upper respiratory tract infection 19.46 14.27 13 43675 91155 79609545
Haemochromatosis 19.44 14.27 11 43677 1339 79699361
Weight increased 19.43 14.27 82 43606 277304 79423396
Plasma cell myeloma 19.36 14.27 3 43685 53256 79647444
Tachycardia 19.27 14.27 43 43645 177725 79522975
Nephrotic syndrome 19.20 14.27 27 43661 11147 79689553
Mucosal inflammation 18.68 14.27 9 43679 75571 79625129
Metabolic acidosis 18.68 14.27 11 43677 82518 79618182
Hepatitis C virus test 18.67 14.27 5 43683 76 79700624
Fibromyalgia 18.63 14.27 6 43682 64334 79636366
Orthostatic hypotension 18.62 14.27 4 43684 56160 79644540
Hypoglycaemia 18.51 14.27 17 43671 101577 79599123
Chronic obstructive pulmonary disease 18.48 14.27 12 43676 85407 79615293
VIIIth nerve lesion 18.42 14.27 4 43684 23 79700677
Portal hypertension 18.28 14.27 21 43667 7087 79693613
Acute respiratory failure 18.25 14.27 5 43683 59536 79641164
Sudden hearing loss 17.99 14.27 12 43676 1957 79698743
Hepatic pain 17.76 14.27 16 43672 4056 79696644
Irritable bowel syndrome 17.68 14.27 6 43682 62235 79638465
Abdominal discomfort 17.64 14.27 74 43614 250653 79450047
Serum ferritin increased 17.22 14.27 24 43664 9823 79690877
Exposure during pregnancy 17.18 14.27 18 43670 101114 79599586
Intentional product use issue 17.14 14.27 36 43652 152076 79548624
Injection site pain 17.05 14.27 28 43660 129810 79570890
Asthma 16.94 14.27 30 43658 135065 79565635
Haemorrhoids thrombosed 16.75 14.27 6 43682 247 79700453
Acquired porphyria 16.66 14.27 4 43684 38 79700662
Prurigo 16.65 14.27 10 43678 1359 79699341
Loss of personal independence in daily activities 16.61 14.27 19 43669 102561 79598139
Unresponsive to stimuli 16.52 14.27 5 43683 55783 79644917
Pregnancy of partner 16.48 14.27 6 43682 259 79700441
Rash erythematous 16.44 14.27 69 43619 57700 79643000
Portal vein thrombosis 16.33 14.27 18 43670 5809 79694891
Drug ineffective for unapproved indication 16.28 14.27 4 43684 51234 79649466
Hepatitis C RNA fluctuation 16.24 14.27 3 43685 6 79700694
Meningitis 16.23 14.27 23 43665 9559 79691141
Nasal congestion 16.23 14.27 11 43677 76541 79624159
Transfusion 16.20 14.27 36 43652 21294 79679406
Homicidal ideation 15.90 14.27 14 43674 3443 79697257
Coronary artery disease 15.88 14.27 8 43680 65466 79635234
Maternal exposure during pregnancy 15.65 14.27 32 43656 136506 79564194
Electrocardiogram QT prolonged 15.46 14.27 16 43672 90370 79610330
Retinal detachment 15.38 14.27 22 43666 9225 79691475
Gait disturbance 15.37 14.27 60 43628 207446 79493254
Hepatorenal syndrome 15.28 14.27 15 43673 4234 79696466
Retinal disorder 15.24 14.27 11 43677 2036 79698664
Aplasia pure red cell 15.12 14.27 20 43668 7790 79692910
Heart rate decreased 15.05 14.27 10 43678 70306 79630394
Optic nerve cupping 15.05 14.27 4 43684 59 79700641
Glossodynia 14.80 14.27 21 43667 103316 79597384
Lymphadenopathy 14.69 14.27 63 43625 53184 79647516
Hepatic fibrosis 14.65 14.27 19 43669 7261 79693439
Folliculitis 14.62 14.27 6 43682 55374 79645326
Cardio-respiratory arrest 14.62 14.27 23 43665 108487 79592213
Swelling 14.60 14.27 65 43623 216646 79484054
Borderline personality disorder 14.56 14.27 8 43680 919 79699781
Mood altered 14.55 14.27 31 43657 17816 79682884
Demyelinating polyneuropathy 14.53 14.27 10 43678 1716 79698984
Amyotrophy 14.52 14.27 7 43681 613 79700087
Bone marrow failure 14.51 14.27 61 43627 51046 79649654
Granulocytopenia 14.51 14.27 24 43664 11407 79689293
Myocardial infarction 14.45 14.27 52 43636 184077 79516623
Haematocrit decreased 14.28 14.27 69 43619 61243 79639457

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L03AB11 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
IMMUNOSTIMULANTS
IMMUNOSTIMULANTS
Interferons
ATC L03AB61 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
IMMUNOSTIMULANTS
IMMUNOSTIMULANTS
Interferons
FDA CS M0025711 Interferon-alpha
FDA EPC N0000175521 Interferon alpha
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000998 Antiviral Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Chronic type B viral hepatitis indication 61977001
Chronic hepatitis C indication 128302006




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Interferon alpha/beta receptor Membrane receptor AGONIST DRUG LABEL DRUG LABEL

External reference:

IDSource
Q46947FE7K UNII
4021362 VANDF
C0391001 UMLSCUI
CHEMBL1201560 ChEMBL_ID
DB00008 DRUGBANK_ID
7871 INN_ID
120608 RXNORM
17012 MMSL
45142 MMSL
d04821 MMSL
009711 NDDF
398841009 SNOMEDCT_US
421559001 SNOMEDCT_US
C100416 MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Pegasys HUMAN PRESCRIPTION DRUG LABEL 1 0004-0350 INJECTION, SOLUTION 180 ug SUBCUTANEOUS BLA 32 sections
Pegasys HUMAN PRESCRIPTION DRUG LABEL 1 0004-0350 INJECTION, SOLUTION 180 ug SUBCUTANEOUS BLA 32 sections
Pegasys HUMAN PRESCRIPTION DRUG LABEL 1 0004-0357 INJECTION, SOLUTION 180 ug SUBCUTANEOUS BLA 32 sections
Pegasys HUMAN PRESCRIPTION DRUG LABEL 1 0004-0357 INJECTION, SOLUTION 180 ug SUBCUTANEOUS BLA 32 sections
Pegasys HUMAN PRESCRIPTION DRUG LABEL 1 82154-0449 INJECTION, SOLUTION 180 ug SUBCUTANEOUS BLA 32 sections
Pegasys HUMAN PRESCRIPTION DRUG LABEL 1 82154-0451 INJECTION, SOLUTION 180 ug SUBCUTANEOUS BLA 32 sections